Navigation Links
Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing
Date:8/25/2014

RARITAN, N.J., Aug. 25, 2014 /PRNewswire/ -- Janssen Diagnostics, LLC today announced the addition of next-generation sequencing (NGS) to the portfolio of services it provides pharmaceutical and academic researchers. With this announcement, Janssen Diagnostics continues to drive innovative solutions for its lab services customers by expanding its lab services offering in rare cell detection beyond its core competencies: the gold-standard CELLSEARCH® System, proteomics, and fluorescent in situ hybridization.

Janssen Diagnostics has entered into an agreement with Asuragen Inc. enabling them to offer NGS to their customers on Asuragen's proprietary SuraSeq™ panels. This NGS platform allows the rapid analysis of DNA and has proven applicability in oncology research. When used in tandem with the CELLSEARCH® System, this technology can provide researchers with a more comprehensive understanding of tumor biology, drug response, and drug resistance through the capture and interrogation of rare cells (circulating tumor cells, circulating multiple myeloma cells, and others captured via the CELLSEARCH® System).

"We are very pleased to offer NGS services to our research customers," commented Kristen Hollingsworth, Global Business Leader, Janssen Diagnostics, LLC. "Our lab services team is focused on giving researchers tools to identify biomarkers that may be clinically relevant, and track their subjects' status over the course of their clinical trials – we call it 'dynamic monitoring'."

Performing NGS on rare cells can help detect hidden biological processes. As an example, NGS on circulating tumor cells (CTCs) provides additional insights for cancer researchers as studies have demonstrated heterogeneity in information obtained from a primary tumor versus that which is measured in detectable CTCs.

About Janssen Diagnostics

At Janssen Diagnostics we are passionate about the promise of personalized medicine and its potential to improve outcomes for specific patients through targeted therapies.

We aspire to help doctors and researchers better identify, prevent or intervene earlier with diseases, or cure people with the right medicines for the right person, at the right time.

Being part of Janssen puts us in a strong position, enabling us to bridge Janssen's extensive pharmaceutical knowledge-base and global capabilities, with our own heritage and talent in research technology, diagnostics and health information technology to deliver integrated solutions into the hands of healthcare providers.

The best way to further our aspirations in the personalized medicine space is to move away from the traditional business model and adopt a more open model that is based on developing the best technologies, either in-house or by partnering with those who own them, to ultimately improve patient outcomes in collaboration with our customers.

What makes Janssen Diagnostics unique is the concentration of minds, personnel and skills at the heart of Pharma R&D, specifically organized to develop and commercialize products and services around meeting patient needs of both today and tomorrow.

Media Contacts:

Frederik Wittock
Janssen Global Services, LLC
fwittock@its.jnj.com or +32 14 60 57 24

Scott Canady
scanady2@its.jnj.com or 809-481-2781


'/>"/>
SOURCE Janssen Diagnostics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Contraceptives Market 2014-2018: Key Vendors are Actavis, Bayer, Johnson & Johnsons, Janssen, Merck & Co, Pfizer and Teva
2. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
3. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
4. Janssen Launches Online Healthy Minds Video Series
5. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
6. Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
7. Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gileads Sofosbuvir and Janssen/Medivirs Simeprevir
8. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
9. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
10. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
11. Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will ... at the Sheraton Hotel in Toronto, Ontario . ... Company is scheduled to present on Tuesday, May 2 at 10:00 ... of the Board, Tony Holler will also attend the ... For more details about ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Patient ... Baltimore Health System, with the 2017 Ruth Ravich Patient Advocacy Award in ... patient advocates. DeVaro was honored with the award at The Beryl Institute’s annual ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... A Week of Addiction and Recovery Education, from April 24 to April 28, ... substance use disorders. , The mission of AWARE is to instill a ...
(Date:4/21/2017)... UK (PRWEB) , ... April 21, 2017 , ... ... for Enterprise in the category of International Trade, the UK’s most prestigious award ... international trade, which represents 95% of total revenues and has grown by a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Westside ... experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become one ... to help my numerous clients over the years with all their dental needs,” said ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
Breaking Medicine News(10 mins):